Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 633-639

  Ueno, Toshiharu ^a,b   Takeda, Kazuhito ^b   Nagata, Michio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b ASO IIZUKA HOSPITAL   (Japan)

Author keywords

proteinuria; renal amyloidosis; rheumatoid arthritis

Indexed keywords

AMYLOID PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; BUCILLAMINE; C REACTIVE PROTEIN; CANDESARTAN; CREATININE; CYCLOPHOSPHAMIDE; ETANERCEPT; LOSARTAN; METHOTREXATE; METHYLPREDNISOLONE; OLMESARTAN; PROTEIN; TACROLIMUS; VALSARTAN;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PRESERVATION; MAINTENANCE DRUG DOSE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE DISTRIBUTION; AGED; AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; BIOPSY, NEEDLE; COMORBIDITY; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84856947162     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr357     Document Type: Article

References (36)

1. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371
2. Gillmore JD, Lovat LB, Persey MR et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596
4. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267-285
5. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458-3471
6. Helin HJ, Korpela MM, Mustonen JT et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995; 38: 242-247
7. Bergesio F, Ciciani AM, Manganaro M et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941-951
8. Reilly PA, Cosh JA, Maddison PJ et al. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-369
9. Kuroda T, Tanabe N, Sato H et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 2006; 26: 1147-1153
10. Kuroda T, Tanabe N, Harada T et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2006; 25: 498-505
11. Komatsuda A, Morita K, Ohtani H et al. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate. Am J Kidney Dis 1998; 32: E7
12. Nakamura T, Yamamura Y, Tomoda K et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003; 22: 371-375
13. Chevrel G, Jenvrin C, McGregor B et al. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2001; 40: 821-825
14. Maezawa A, Hiromura K, Mitsuhashi H et al. Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 1994; 42: 30-32
15. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38: 1851-1854
16. Millet A, Rioux-Leclercq N, Le Lay JP et al. Unexpected remission of renal AA amyloidosis associated with rheumatoid arthritis. Joint Bone Spine 2009; 76: 431-432
17. Nakamura T, Higashi S, Tomoda K et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 518-522
18. Ravindran J, Shenker N, Bhalla AK et al. Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatology (Oxford) 2004; 43: 669-672
19. Elkayam O, Hawkins PN, Lachmann H et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002; 46: 2571-2573
20. Kuroda T, Otaki Y, Sato H et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int 2008; 28: 1155-1159
21. Gottenberg JE, Merle-Vincent F, Bentaberry F et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48: 2019-2024
22. Simsek I, Kaya A, Erdem H et al. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 2010; 23: 119-123
23. Drewe E, Huggins ML, Morgan AG et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004; 43: 1405-1408
24. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000
25. Verine J, Mourad N, Desseaux K et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007; 38: 1798-1809
26. Shiiki H, Shimokama T, Yoshikawa Y et al. Renal amyloidosis. Correlations between morphology, chemical types of amyloid protein and clinical features. Virchows Arch A Pathol Anat Histopathol 1988; 412: 197-204
27. Solez K, Colvin RB, Racusen LC et al. The Banff 97 working classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760
28. Fernández-Nebro A, Olivé A, Castro MC et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 2010; 123: 454-461
29. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2006; 49: 12-26
30. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140
31. Laverman GD, Henning RH, de Jong PE et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381-1384
32. Joss N, McLaughlin K, Simpson K et al. Presentation, survival and prognostic markers in AA amyloidosis. QJM 2000; 93: 535-542
33. Katafuchi R, Taguchi T, Takebayashi S et al. Proteinuria in amyloidosis correlates with epithelial detachment and distortion of amyloid fibrils. Clin Nephrol 1984; 22: 1-8
34. Takano Y, Yamauchi K, Hayakawa K et al. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 2007; 581: 421-426
35. Mathieson PW. Proteinuria and immunity-an overstated relationship? N Engl J Med 2008; 359: 2492-2494
36. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938